Browsing by Author "Gonzalez-Juarrero, Mercedes, advisor"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Open Access An evaluation of biological responses to model biomaterials in vivo and in vitro(Colorado State University. Libraries, 2009) Chamberlain, Lisa M., author; Gonzalez-Juarrero, Mercedes, advisorThe use of in vitro and in vivo models to study inflammatory responses is extremely common in the pre-clinical evaluation of implantable materials and anti-inflammatory drugs. In this body of work we performed comparative studies of the inflammatory responses elicited by different biomaterials when interacting with cells in the implanted host. The results demonstrate first the non-equivalence between immortalized cell lines and primary-derived cell types in the inflammatory response and second temporal effects on differences in responses. Additionally, differences between in vivo and in vitro models are clearly demonstrated, and potential differences between our in vivo and other published models are seen. The results obtained from this comparative study will help to explain many discrepancies found between previous studies reported in the literature.Item Open Access Characterization of Brucella infection in ruminant hosts: disease pathogenesis, immunology, and epidemiology(Colorado State University. Libraries, 2015) Higgins, Jennifer, author; Bowen, Richard A., advisor; Gonzalez-Juarrero, Mercedes, advisor; Nol, Pauline, committee member; Callan, Robert J., committee memberBrucellosis is one of the most common zoonotic diseases worldwide, with endemic disease areas in the Middle East, Mediterranean Basin, Central Asia, Africa, and Central and South America. Disease is caused by various species of the gram negative bacteria Brucella. Infection in humans results primarily from contact with infected livestock or consumption of contaminated livestock products; cattle, small ruminants, and swine are the primary reservoir hosts. Although the Brucella bacterium was discovered over a century ago, control of disease remains a major challenge in many areas worldwide. Research on this pathogen has mostly been conducted in mouse models, which are naturally resistant to infection. Little is known of the immune response of natural ruminant hosts to Brucella infection. Here we report an epidemiological study of brucellosis in Mongolia, as well as an experimental infection study of pregnant goats with two strains of B. melitensis – 16M, a fully virulent strain, and Rev. 1, a reduced virulence vaccine strain. Design of the experimental infection study was influenced by findings from field research in an endemic disease region. The objectives of the experimental challenge study were to characterize clinical disease, shedding, and tissue burdens in infected animals. The cellular immune response was then compared in animals infected with the two B. melitensis strains with the aim of identifying components of the protective response induced by the Rev. 1 vaccine strain and deficits in the immune response elicited by infection with virulent B. melitensis 16M. A fluorescence polarization assay was utilized to identify antibodies in milk samples and estimate the proportion of Brucella positive cattle, yak, and hybrids in three regions of Mongolia. Additionally, prevalence of brucellosis in herd owners was assessed via questionnaire. Information was also collected from herd owners regarding animal husbandry practices and herd health in order to identify individual-and herd-level characteristics that are predictive for brucellosis. The study indicates that brucellosis remains endemic in cattle, yak, and hybrids within Bulgan and Khuvsgul provinces of Mongolia despite a national control program. Herd level prevalence was determined to be 10.4% in the 77 herds tested. High levels of human disease were also reported. Results of the study indicate that the Mongolian brucellosis control program must be critically evaluated if the national goal of obtaining brucellosis-free status by 2021 is to be realized. In an experimental challenge study, pregnant does infected with B. melitensis 16M at midgestation had an 86% abortion rate, while no Rev. 1-infected does aborted. Fetal infection rate was 92% and 43% in kids of 16M- and Rev. 1-infected does, respectively. Widespread tissue colonization was noted in 100% of 16M-infected does, and all of these animals shed brucellae in milk and vaginal secretions. Infection in does inoculated with Rev. 1 was more variable with only one animal showing generalized infection and colonization at levels similar to that of 16M-infected animals. Other Rev. 1-innoculated animals showed low levels of focal infection and shedding. Here we report the first isolation of B. melitensis from muscle tissue of experimentally infected goats. Milk was also found to pose a significant public health risk with three 16M-infected animals consistently shedding brucellae at levels of 104 – 107 CFU/ml over the four days on which samples were collected postpartum. Despite the clear differences in clinical disease resulting from infection with the two strains of B. melitensis, protective versus deficient components of the immune response elicited by these two strains remain undefined. A pro-inflammatory response characterized by increases in granulocytes, monocytes, and CD4+ lymphocytes was identified by flow cytometric analysis of blood from 16M-infected does. In comparison cell numbers remained consistent with pre-infection levels in Rev. 1-inoculated animals. Limited production of IFN-γ and low level expression of the CD25 activation marker indicate a potential anergic state of CD4+ T cells in B. melitensis-infected goats. Increased numbers of IFN-γ producing WC1+ gamma-delta T cells at 28 days post-infection in Rev. 1-inoculated goats in comparison to 16M-infected animals may suggest a role of this cell type in the protective response elicited by the Rev. 1 vaccine strain. The research presented in this dissertation builds upon current knowledge of Brucella epidemiology, pathogenesis, and immunology in natural ruminant hosts. The work provides a strong framework from which further comparative investigations of immune response to virulent B. melitensis and the reduced virulence B. melitensis vaccine strain, Rev. 1, can be conducted with the ultimate goal of defining components of a protective versus deficient response to Brucella in a natural host. This will ultimately aid in development of improved vaccines facilitating control of disease in endemic areas like Mongolia.Item Open Access Inhalational antibiotic therapy for treatment of chronic pulmonary Mycobacterium abscessus disease in mice(Colorado State University. Libraries, 2019) Pearce, Camron, author; Gonzalez-Juarrero, Mercedes, advisor; Jackson, Mary, committee member; Volckens, John, committee memberMycobacterium abscessus (M. abscessus) is a nontuberculous mycobacterium that causes chronic pulmonary infections. Due to M. abscessus's intrinsic antibiotic resistance, treatment is often complex with low cure rates. Tigecycline, a glycylcycline class antibiotic, demonstrates bactericidal effects against M. abscessus without eliciting bacterial resistance mechanisms, however, this antibiotic requires intravenous administration and causes significant side effects that limit its use. Here, we tested the hypothesis that tigecycline administered via inhalation has the potential to maximize the bactericidal effect while reducing side effects. GM-CSF knockout mice with pulmonary M. abscessus infection were treated by intrapulmonary tigecycline aerosols in 0.25 mg, 1.25 mg, and 2.50 mg doses for 28 days. Assessment of pulmonary bacterial burden after full treatment duration shows that inhaled tigecycline is highly effective, dose-dependent, and well tolerated. We concluded that inhaled tigecycline represents a viable treatment option for M. abscessus pulmonary disease. Future studies should address the pharmacokinetics, and ultimately, translation into clinical trials.Item Open Access Minipigs as a neonatal animal model for TB vaccine efficacy(Colorado State University. Libraries, 2016) Ramos Arriaza, Laylaa, author; Gonzalez-Juarrero, Mercedes, advisor; Bowen, Richard, committee member; Izzo, Angelo, committee member; Guth, Amanda, committee member; Dow, Steven, committee memberCurrently, the only vaccine available to prevent tuberculosis (TB) is Bacillus Calmette-Guerin (BCG). The vaccine lacks efficacy against pulmonary disease or reactivation of latent TB but prevents disseminated TB in children and is thus widely used in countries with endemic TB as part of the neonatal vaccine regimen. There are several new vaccines that have shown efficacy against TB in adult animal models yet fail to protect infants from TB disease in clinical trials. Failure in the development of new pediatric vaccines may be due to incomplete knowledge in the elicited immune response to BCG vaccination and testing of vaccine efficacy in adult rather than neonatal animal models. In this novel approach, we used the mini-pig as a neonatal animal model for evaluation of immune responses to BCG vaccine. We demonstrate young mini-pigs are susceptible hosts to the highly virulent Mycobacterium tuberculosis (Mtb) strain, HN878 and that the pathological course of infection resembles that seen in human TB. In this study we longitudinally monitored the immune response of neonatal mini-piglets vaccinated with BCG until adulthood, with the same monitoring applied to a group of unvaccinated mini-piglets. Further, we challenged both vaccinated and non-vaccinated animals via the aerosol route with HN878 and we characterized important changes between the two groups in the course of immune responses following challenge. Based on comparison of immune responses to BCG in mini-pigs and infants, our findings suggest that mini-pigs have the potential to serve as an effective neonatal animal model for TB vaccine development.Item Open Access The effects of mannose capped lipoarabinomannan on dendritic cell function(Colorado State University. Libraries, 2009) Lee, Eric John, author; Gonzalez-Juarrero, Mercedes, advisor; Schenkel, Alan, committee member; Chen, Chaoping, committee memberM. tuberculosis is one of the leading causes of death due to infectious disease in the world. While the majority of people are capable of controlling the initial infection, many progress to a latent stage of disease where the M. tuberculosis bacilli persist for long periods of time within the host. The M. tuberculosis cell wall lipoglycan mannose capped lipoarabinomannan (ManLAM) has been characterized as one of the immunomodulatory factors associated with the bacteria [3-5]. ManLAM interacts with dendritic cells (DCs) via DC-SIGN, mannose receptors and to a lesser extent TLR-2 [6-8]. Thus we set out to examine the effects that ManLAM has on DCs both in vitro and in vivo. ManLAM treatment of bone marrow derived DCs (BMDCs) prevents their phenotypic maturation reduces the expression of MHC class II and CD1d. BMDCs stimulated with ManLAM also exhibit altered phagocytic capacity and the inability to stimulate naïve CD4+ T-cell proliferation.